At the intersection of primary pulmonary myxoid sarcoma and pulmonary angiomatoid fibrous histiocytoma: observations from three new cases by Smith, Steven C et al.
At the intersection of primary pulmonary
myxoid sarcoma and pulmonary
angiomatoid fibrous histiocytoma:
observations from three new cases
DOI: 10.1111/his.12354
© 2014 John Wiley & Sons Ltd.
Sir: Twin recent reports identified a novel entity, pri-
mary pulmonary myxoid sarcoma (PPMS)1 and an
endobronchial presentation of angiomatoid fibrous
histiocytoma (AFH).2 PPMS were described as 20–
40-mm diameter endobronchial, lobulated neoplasms
occurring in young patients (mean age 45 years),
and comprising polygonal to spindled cells within a
myxoid stroma evocative of extraskeletal myxoid
chondrosarcoma (EMC).1,3 In contrast to EMC, seven
of nine testable cases harboured EWSR1–CREB1
fusions. Nine of 10 showed remarkable associated
inflammation, which was focal to follicular to lym-
phoplasmacytic. Two of six patients for whom follow-
up was available developed metastases (brain and
kidney), supporting classification as a low-grade
sarcoma.1 One additional patient had no recurrence.4
Two cases of endobronchial AFH2 showed a charac-
teristic multinodular growth pattern of bland, ovoid
to spindled cells with a peritumoral lymphoplasmacy-
tic cuff, a fibrotic capsule, and strong focal desmin
expression (without classic blood-filled ‘angiomatoid’
spaces). Similarly to reports of eight AFHs occurring
in unusual sites,5 including the lung, both endobron-
chial AFHs showed focal myxoid change.2 One lesion
harboured an EWSR1–CREB1 fusion, and the other
harboured an EWSR1–ATF1 fusion. Neither of the
patients (males aged 61 and 64 years) has suffered
recurrence.2
To emphasize the recent recognition of this entity,
we report three additional patients with what we
termed PPMS, seen in consultation, recognizing over-
lap with what might be considered pulmonary AFH.
Patient 1 was a 66-year-old woman who presented
with a 2-year history of intermittent pulmonary
obstructive symptoms and pneumonia, at which time
her tumour was discovered on a chest computed
tomography (CT) scan. Her resected left upper lobe
showed a pale 40-mm diameter endobronchial mass,
with associated postobstructive consolidation.
Microscopically, her endobronchial-based tumour
(Figure 1A) infiltrated into peribronchial pulmonary
parenchyma. Over 80% of the lesion showed polygo-
nal to spindled cells with a reticular, myoepithelial-
type appearance and mild atypia in a pink–grey
myxoid stroma (Figure 1B). A peritumoral fibrous cuff
was present, particularly at the interface with alveolar
parenchyma (Figure 1C). The lesion was negative
for pancytokeratin, p63, S100, and desmin, and
showed patchy EMA-positive cells; break-apart
fluorescence in-situ hybridization (FISH) was positive
for both EWSR1 (Figure 1D) and CREB1 (negative for
ATF1).
Patient 2 was a 28-year-old man presenting with
4 months of cough with haemoptysis. Imaging
showed an 85-mm diameter right lower lobe mass
described grossly as obliterating the bronchus. Micro-
scopically, this tumour was a lobular, biphasic lesion,
~40% of which was composed of myxoid pools
(Figure 1E). The remainder showed exuberant fibroin-
flammatory reaction with confluent plasma cells.
Two foci showed ‘angiomatoid’ blood-filled spaces
(Figure 1F). Moderate atypia was present (more than
in patient 1) among reticular and clustered cells float-
ing in the distinctive EMC-type stroma (Figure 1G).
The lesion was negative for pancytokeratin, p63 and
S100, showed focal EMA positivity, but was strongly
positive for desmin, visible against the inflammatory
background and discontinuous peritumoral fibrous
capsule (Figure 1H). FISH was positive for EWSR1
rearrangement, but not for CREB1 or ATF1
rearrangements.
Patient 3 was another 28-year-old man, who
presented with a 2-week history of chest pain. A CT
scan showed a 60-mm diameter lesion in the right
upper lobe of the lung. At low magnification, the
tumour showed a destructive growth pattern, with
focal necrosis and infiltration from an endobronchial
base into adjacent lung parenchyma (Figure 1I). At
higher power, the degree of atypia was severe
(Figure 1J), and the myxoinflammatory areas (80% of
the lesion) expanded to undermine the bronchial
epithelium (Figure 1K). As in case 1, the lesion was
negative for keratins, p63, and S100, and there were
rare EMA-positive cells. FISH was negative for
rearrangement at EWSR1 (Figure 1L), CREB1, and
ATF1.
Taken together, these lesions span a spectrum from
PPMS to AFH in terms of morphology, atypia, and
molecular findings. The varying proportion of the
myxoid component, from 40% to 80%, is greater than
that described for AFH cases in the lung.2,5,6 Case 2
showed a degree of plasmacytic inflammation, a fibro-
tic component, and desmin positivity, none of which
were included in previous descriptions of PPMS,1,4
with ‘angiomatoid’ foci that have not yet been
reported in endobronchial AFH2 or PPMS cases.1,4 All
three cases showed at least a focal peritumoral fibrous
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cuff, although nodular proliferations of bland ovoid
cells characteristic of AFH were only seen focally in
case 2. All three lesions were diagnosed as PPMS, to
underscore our concern for risk of recurrence (partic-
ularly since each tumour was larger than previously
reported PPMS or pulmonary AFH cases1,2,4), with
recognition of the AFH-overlapping features noted
especially in case 2. All three patients are disease free
at 18, 16 and 4 months post-resection.
We note that EWSR1 rearrangements were present
in only two of our patients. Given prior observation
of a subset of PPMS without identifiable rearrange-
ments1 and of AFH of unusual sites showing
rearrangement at the FUS locus (rather than
EWSR1),5,7,8 emerging technologies such as RNA
sequencing may be more suitable for comprehensive
molecular assessment as a larger number of these
cases are assembled and studied. Taken together, the
clinical, histopathological and immunophenotypic
findings of these cases were sufficiently distinctive to
support a diagnosis of PPMS, recognizing the absence
of clearly defined diagnostic criteria, particularly with
reference to molecular findings. Our experience sup-
ports a previous suggestion2 that PPMS and AFH of
the lung may represent an overlapping morphological
and biologic spectrum; multi-institutional efforts to
study the morphological, clinical and molecular fea-
tures of larger cohorts may be helpful in establishing
diagnostic criteria and assessing the biological poten-
tial of these lesions.
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Figure 1. Three cases of primary pulmonary myxoid sarcoma versus angiomatoid fibrous histiocytoma. A–D, Case 1 was an endobronchial
lesion with reticular spindle cells in myxoid stroma (A), mild atypia (B), a focal perilesional fibroinflammatory cuff (C), and rearrangement at
EWSR1 (D) and CREB1. E–H, Case 2 showed exuberant inflammation (E), angiomatoid areas (F), moderate cellular atypia (G), desmin
positivity (H), and rearrangement at EWSR1, but not at CREB1 or ATF1. I–L, Case 3 showed an expansile, high-grade, focally necrotic mass
(I) with severe atypia (J), undermining the bronchial epithelium (K); rearrangements at EWSR1 (L), CREB1 or ATF1 were not detected.
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Sir: Lichen sclerosus (LS) is a chronic mucocutaneous
inflammatory disorder that most commonly affects
the anogenital skin and occurs more frequently in
females than in males.1 Clinically, it presents as
white, sometimes painful, pruritic papules or plaques.
Despite its predilection for the anogenital regions the
condition can occur throughout the body, although
lesions of the oral mucosa are exceedingly rare and
those involving the gingiva are even more so.2,3 In
the oral mucosa LS is seen typically in middle-aged
females, the most common sites being the lower lip,
buccal mucosa and upper lip.2 An increased risk of
genital squamous cell carcinoma (SCC) has been doc-
umented in genital LS, thus resulting in an increased
need for close follow-up and management of affected
patients.1,2 Malignancy involving oral cases of LS,
however, has not been reported.2 First-line treatment
of LS typically involves the use of topical corticoster-
oids; nevertheless, the condition is not cured and
remissions do not usually occur.1
Histologically, LS is characterized by an atrophic
thinned epidermis with blunted rete ridges, hydropic
degeneration of the basal layer, and dermal collagen
sclerosis with an underlying band of lymphocytic
infiltrate. These features tend to overlap in both skin
and oral mucosal lesions.2,3
The underlying aetiology of LS remains unidenti-
fied; however, several possible causes have been sug-
gested, ranging from chronic irritation to an
autoimmune component, as well as infectious
causes.1 Infection with Borrelia burgdorferi, the causa-
tive organism of Lyme disease, has been proposed as
a possible aetiology, due to a similarity in their histo-
logical features and the identification of Borrelia
organisms in some cases of LS.4 Evidence of this asso-
ciation has remained conflicting over the years, due
in part to the overall lack of consistency in identify-
ing Borrelia in many LS cases and in general.1,5,6
Furthermore, LS does not appear to have predomi-
nantly infectious characteristics, as there has been
only a single case report of LS occurring in sexual
partners.5 This does not, however, discount the possi-
bility that LS is a reactive process occurring in Bor-
relia-infected skin or soft tissue. It is interesting to note
that the various instances of Borrelia involvement of
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